← Leaderboards
Uwe Rix
H. Lee Moffitt Cancer Ctr & Res Inst
$4,190,386
Attributed
$6,083,017
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $990K · FY2015–24$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,083,017 · 5
By mechanism
R01$4,806,717 · 2
R21$1,276,300 · 3
Top collaborators
- Eric B. Haura6 shared
- Andrii Monastyrskyi2 shared
- Alvaro N Monteiro2 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Eric B. Haura$11,744,471
- Andrii Monastyrskyi$1,496,168
- Alvaro N Monteiro$2,690,824
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionPharmaceutical PreparationsCellsCell LineLeadRna InterferenceProteomicsProteinsNew Therapeutic TargetCancer CellMalignant Neoplasm Of LungResistanceMalignant NeoplasmsInnovationSignal PathwayPatient PopulationDesignComplexCombined Modality TherapyBaseDrug TargetingMissionProteomeLung
Grant awards (15)
Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets$187,087
R21 · FY2024 · CA · contact PI
Overcoming resistance to KRAS inhibitors through a fragment-based chemoproteomics approach$433,256
R21 · FY2023 · CA
Integrated fragment-based phenotypic screening and chemoproteomics for identification of novel small cell lung cancer-specific targets$236,321
R21 · FY2023 · CA · contact PI
RESISTANCE AND RESPONSE SIGNALING TO PARP1 INHIBITORS IN OVARIAN CANCER$188,644
R21 · FY2022 · CA
Targeting bidirectional signaling in lung stroma and cancer cells$478,243
R01 · FY2021 · CA · contact PI
RESISTANCE AND RESPONSE SIGNALING TO PARP1 INHIBITORS IN OVARIAN CANCER$230,992
R21 · FY2021 · CA
Targeting bidirectional signaling in lung stroma and cancer cells$506,795
R01 · FY2020 · CA · contact PI
Targeting bidirectional signaling in lung stroma and cancer cells$491,590
R01 · FY2019 · CA · contact PI
Harnessing beneficial off-target effects of kinase inhibitors in lung cancer$447,719
R01 · FY2019 · CA · contact PI
Targeting bidirectional signaling in lung stroma and cancer cells$526,874
R01 · FY2018 · CA · contact PI
Harnessing beneficial off-target effects of kinase inhibitors in lung cancer$463,136
R01 · FY2018 · CA · contact PI
Targeting bidirectional signaling in lung stroma and cancer cells$505,460
R01 · FY2017 · CA · contact PI
Harnessing beneficial off-target effects of kinase inhibitors in lung cancer$464,563
R01 · FY2017 · CA · contact PI
Harnessing beneficial off-target effects of kinase inhibitors in lung cancer$461,493
R01 · FY2016 · CA · contact PI
Harnessing beneficial off-target effects of kinase inhibitors in lung cancer$460,844
R01 · FY2015 · CA · contact PI